Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, LS2 9JT, United Kingdom.
Gender Identity Service, The Newsam Centre, Seacroft Hospital, Leeds LS14 6UH, United Kingdom.
Best Pract Res Clin Endocrinol Metab. 2024 Sep;38(5):101921. doi: 10.1016/j.beem.2024.101921. Epub 2024 Aug 3.
Gender incongruence and the number of people seeking gender affirming hormone treatment has dramatically risen in the last two decades. In the UK, transgender women and non-binary transfeminine individuals are typically treated with simultaneous suppression of endogenous testosterone production through anti-androgens and exogenous oestradiol replacement. Oestrogen replacement comes in different forms and is primarily given as transdermal (gel or patch) or oral preparations in the UK. Decisions around preparation choice are based on a combination of individual preference and/or mitigating the chance of complications based on individual risk profiles. Time frames to achieve female physical changes are largely predictable and managing expectations of individuals prior to commencing treatment is highly important. Common complications include venous thromboembolism, liver dysfunction and effects on fertility, thus individuals should be thoroughly counselled prior to commencing treatment. This article provides an overview of the management and considerations of gender-affirming hormone treatment in transgender women and non-binary transfeminine individuals.
在过去的二十年中，性别不一致和寻求性别肯定激素治疗的人数急剧增加。在英国，跨性别女性和非二进制跨女性个体通常通过抗雄激素同时抑制内源性睾酮的产生和外源性雌激素替代治疗。雌激素替代有不同的形式，在英国主要以透皮（凝胶或贴片）或口服制剂给予。制剂选择的决定基于个体偏好和/或根据个体风险概况降低并发症发生几率的综合考虑。实现女性身体变化的时间框架在很大程度上是可以预测的，在开始治疗前管理好个体的期望非常重要。常见的并发症包括静脉血栓栓塞、肝功能障碍和对生育能力的影响，因此在开始治疗前应对个体进行彻底咨询。本文概述了跨性别女性和非二进制跨女性个体的性别肯定激素治疗的管理和注意事项。
